Non-nucleoside reverse transcriptase inhibitor + reverse transcriptase inhibitors (nucleoside + nucleotide analogue). Efavirenz activity is mediated predominantly by noncompetitive inhibition of ...

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that is mediated predominantly by noncompetitive inhibition of HIV-1 reverse transcriptase. Swallow whole; do not break tabs.

This medication is a non-nucleoside reverse transcriptase inhibitor (NNRTI), and active antiretroviral therapy (HAART) prescribed for the treatment of human immunodeficiency virus (HIV) type 1 ...

Spanish researchers found that high plasma efavirenz levels correlated with CNS symptoms even after weeks or months of treatment. However, in a substudy of an ACTG trial, late neuropsychiatric ...

Patients stopping efavirenz-based combination therapy might be well advised to continue their NRTIs for 24 to 48 hours after discontinuing efavirenz to avoid prolonged NNRTI monotherapy.

This fixed-dose tablet combines 600mg efavirenz, 200mg emtricitabine (FTC), and 245mg tenofovir disoproxil fumarate (TDF). Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI), ...

Efavirenz/emtricitabine/tenofovir disoproxil fumarate are medications used to treat HIV. They are antiretroviral drugs combined in one pill, taken once a day. Two of the drugs (emtricitabine and ...